Elgin Ufuk, Sen Emine, Çolak Salih, Yılmazbas Pelin
University of Health Sciences, Ulucanlar Eye Education and Research Hospital, Ulucanlar caddesi No:59, 06240, Altindag, Ankara, Turkey.
Int Ophthalmol. 2019 Jun;39(6):1211-1217. doi: 10.1007/s10792-018-0926-y. Epub 2018 Apr 25.
To investigate the outcomes of trabeculectomy with 5-fluorouracil (5-FU) with or without subconjunctival bevacizumab in the surgical management of pseudoexfoliation glaucoma (PXG).
This retrospective study consisted of 49 cases with PXG who underwent initial trabeculectomy with 5-FU. The cases were divided into two age- and sex-matched groups. In 23 cases, subconjunctival bevacizumab was injected (1.25 mg/0.05 mL) at the end of the surgery and in 26 of them the surgery was performed without bevacizumab. The groups were evaluated for the postoperative differences of the intraocular pressure (IOP) and the number of the anti-glaucomatous medications. Independent t, Kolmogorov-Smirnov and Chi square tests were used for statistical analysis.
The mean preoperative IOP was 30.91 ± 4.50 mmHg under the mean number of 2.4 ± 0.7 drops in bevacizumab group. The IOP decreased to 10.22 ± 2.63 mmHg (first week), 10.91 ± 1.88 mmHg (first month), 12.35 ± 2.5 mmHg (3rd month), 12.65 ± 2.35 mmHg (sixth month) and 12.7 ± 1.9 mmHg at the final visit. The mean preoperative IOP was 31.27 ± 5.60 mmHg under the mean number of 2.3 ± 0.7 drops in without bevacizumab group. The IOP decreased to 10.08 ± 2.59 mmHg (first week), 11.00 ± 1.87 mmHg (first month), 12.81 ± 2.04 (3rd month), 13.62 ± 2.21 mmHg (sixth month) and 12.9 ± 2.4 mmHg at the final visit. In both groups, IOP reduced significantly postoperatively. There were no significant differences between the preoperative and the postoperative IOP values.
The additional benefit of single dose of intraoperative bevacizumab was not observed in trabeculectomy with 5-FU in PXG.
探讨小梁切除术联合5-氟尿嘧啶（5-FU），术中联合或不联合结膜下注射贝伐单抗治疗剥脱性青光眼（PXG）的手术效果。
本回顾性研究纳入49例行初次小梁切除术联合5-FU治疗的PXG患者。将患者按年龄和性别匹配分为两组。23例患者在手术结束时结膜下注射贝伐单抗（1.25mg/0.05mL），26例未注射贝伐单抗。评估两组患者术后眼压（IOP）及抗青光眼药物使用数量的差异。采用独立样本t检验、柯尔莫哥洛夫-斯米尔诺夫检验和卡方检验进行统计学分析。
贝伐单抗组术前平均眼压为30.91±4.50mmHg，平均使用抗青光眼药物2.4±0.7滴。术后第1周眼压降至10.22±2.63mmHg，第1个月降至10.91±1.88mmHg，第3个月降至12.35±2.5mmHg，第6个月降至12.65±2.35mmHg，末次随访时为12.7±1.9mmHg。未注射贝伐单抗组术前平均眼压为31.27±5.60mmHg，平均使用抗青光眼药物2.3±0.7滴。术后第1周眼压降至10.08±2.59mmHg，第1个月降至11.00±1.87mmHg，第3个月降至12.81±2.04mmHg，第6个月降至13.62±2.21mmHg，末次随访时为12.9±2.4mmHg。两组患者术后眼压均显著降低。术前和术后眼压值无显著差异。
在PXG患者小梁切除术联合5-FU治疗中，未观察到术中单次使用贝伐单抗的额外益处。
